CDK6 and T-cell acute lymphoblastic leukemia: Accordingly, simultaneous inhibition of the mTOR pathway and CDK6 activity by palbociclib exerted greater antitumor activity than either treatment alone, both in vitro in human T cell acute lymphoblastic leukemia/lymphoma and in vivo [45].